Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of neuromodulators for aesthetic and therapeutic applications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is in various stages of clinical trials for conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. Additionally, Revance is developing DAXI for aesthetic applications, including forehead and lateral canthal lines. The company also offers RT001, a topical botulinum toxin for cosmetic and dermatologic uses. Revance has established collaborations for the development of a biosimilar to BOTOX with Mylan, enhancing its portfolio in the competitive aesthetic market. Founded in 1999 and previously known as Essentia Biosystems, Revance is headquartered in Newark, California, and aims to innovate within the fields of dermatology and aesthetic medicine.